← Eichor
Study identifier: NCT06822205 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Identification and Treatment of Renal Stenosis in Transplanted Kidneys

Condition: Renal Artery Stenosis  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseN/A
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Renal artery stenosis is a complication that may follow kidney transplantation1-5. Renal artery stenosis greater than 50% of the lumen of the artery, associated with clinical symptoms or laboratory worsening of renal function, may lead to transplant failure, however, the indications for treatment and the modalities of treatment remain, to date, a debated topic in the literature. The guidelines of the European Society of Urology recommend endovascular treatment as the first-line treatment by means of angioplasty and/or stent placement6. A recent review of the literature7 examined the results of 56 studies: the results fully support endovascular treatment of the disease which appears to be effective and with a low rate of complications.

This description comes directly from the study's public registry record.

Talk to the study team

Mauro Gargiulo, MD  ·  0512143288  ·  mauro.gargiulo2@unibo.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS AOU di Bologna Policlinico di Sant'OrsolaBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06822205